Searched for
SWISS BIOTECH GIANT
Natco wins patent battle to launch generic 'Risdiplam'A Delhi High Court ruling favors Natco Pharma against Roche's rare disease drug. Natco can now launch generic risdiplam, used for spinal mu...- Roche India head Lara Bezerra set to exitA Roche India spokesperson confirmed the development and said an announcement for a new India head will be made soon. “Dec. 1 will be the d...
- Lara Bezerra to take over as Roche Products India MDLara has over 24 years of experience in the pharmaceutical industry and was earlier the general manager of Roche Venezuela.
- Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, MylanBiocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech ...
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...
- Delhi HC asks government if it approved Biocon’s trastuzumab for three cancersBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- Court battle over Zydus Cadila's breast cancer drug continuesLegal experts said that the court is still in the process of hearing arguments from both sides to ascertain whether Roche could have approa...
- Court defers decision on Roche's plea against Zydus' cancer drugRoche sued Zydus Cadila and the DCGI last week, alleging that the Indian company launched its product, Vivitra, in the country without gene...
- Now, Roche takes Zydus Cadila to court over breast cancer drugThe petition states the approval of Cadila’s drug as a biosimilar has caused Roche “irreparable damage” in violation of applicable law for ...
- Roche, Biocon clash accusing contempt of courtRoche did not comment on the development, stating that the matter was sub judice. Biocon did not respond to ET's queries.
- Government set to release revised biosimilar guidelines in July 2016The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...
- Reliance Life Sciences appeals marketing restrictions on breast cancer drugThe counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...
- Biotech giant Roche takes NPPA to court over cap on injection priceOn May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.
- Delhi High Court asks Roche to explain lawsuit over Avastin copyRoche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.
- Roche moves court to block copies of cancer drug Avastin, A La HerceptinRoche has challenged the regulator and pleaded to block the approvals of the drugs under review, ET learned from highly placed legal source...
- Roche begins probe into Avastin use for eye ailmentsRoche has initiated an internal investigation following reports the it had been used in certain eye ailments and damaged the vision of 15 p...
- Swiss drugmaker Roche completes Genentech takeoverSwiss pharmaceutical giant Roche said it has completed its $46.8 billion takeover of California-based biotech firm Genentech.
- Clubs India with US, EU & RussiaWhat makes India important to the Swiss?
- Merck to acquire biotech firm Serono for $13.3 bnGerman drugmaker Merck unveiled a surprise 16.6-bn-Swiss franc ($13.3 bn) deal to buy Swiss biotech firm Serono on Thursday, creating a new...
Load More
